Iovance Biotherapeutics
Update in progressIOVA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Iovance Biotherapeutics, Inc. is a commercial-stage biopharma focused on autologous tumor-infiltrating lymphocyte therapies for metastatic melanoma and other solid tumors, in the U.S. and abroad. Its programs include Amtagvi, lifileucel, LN-145 series, IOV-2001, IOV-4001, and IOV-3001, with collaborations with NIH, NCI, Cellectis, Novartis, and Boehringer Ingelheim. Formerly Lion Biotechnologies, it is headquartered in San Carlos, California, and was founded in 2007.
Company score
- Sentiment
- -0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.11
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- -0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Frederick G. Vogt Esq., J.D., Ph.D.
- Founded2007
- Employees975
- Websitewww.iovance.com
Identifiers
- ISINUS4622601007
- FIGIBBG000FTLBV7
- LEI549300220Z2GHH33XL82
- CUSIP37182R102
- CIK0001425205